Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Assets (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Assets for 3 consecutive years, with $130.9 million as the latest value for Q4 2025.

  • For Q4 2025, Assets fell 37.52% year-over-year to $130.9 million; the TTM value through Dec 2025 reached $130.9 million, down 37.52%, while the annual FY2025 figure was $130.9 million, 37.52% down from the prior year.
  • Assets hit $130.9 million in Q4 2025 for Artiva Biotherapeutics, down from $148.9 million in the prior quarter.
  • Across five years, Assets topped out at $225.6 million in Q3 2024 and bottomed at $75.9 million in Q2 2024.
  • Average Assets over 3 years is $157.1 million, with a median of $159.1 million recorded in 2025.
  • On a YoY basis, Assets climbed as much as 123.14% in 2025 and fell as far as 37.52% in 2025.
  • Artiva Biotherapeutics' Assets stood at $105.1 million in 2023, then soared by 99.38% to $209.6 million in 2024, then crashed by 37.52% to $130.9 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $130.9 million, $148.9 million, and $169.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.